Stocks and Investing
Stocks and Investing
Mon, July 8, 2024
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
[ Mon, Jul 08th 2024
] - WOPRAI
Mike Matson Reiterated (ATRC) at Strong Buy and Held Target at $40 on, Jul 8th, 2024
Mike Matson of Needham, Reiterated "AtriCure, Inc." (ATRC) at Strong Buy and Held Target at $40 on, Jul 8th, 2024.
Mike has made no other calls on ATRC in the last 4 months.
There are 3 other peers that have a rating on ATRC. Out of the 3 peers that are also analyzing ATRC, 0 agree with Mike's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Mike
- Robbie Marcus of "JP Morgan" Maintained at Buy with Decreased Target to $34 on, Thursday, May 2nd, 2024
- William Plovanic of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $49 on, Thursday, May 2nd, 2024
- Suraj Kalia of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $32 on, Tuesday, April 23rd, 2024
Contributing Sources